Released Aug 9, 2022, before the open
10-Q filed Aug 9, 2022, 40 days after period end · 0001628280-22-021958
Q2 2022 · 10-Q
Revenue$4.49M$4.49M +1,509.3% vs Q2 2021+14.5% vs Q1 2022
Net Income-$27.31M-$27.31M N/M vs Q2 2021N/M vs Q1 2022
EPS Diluted-$0.66-$0.66 N/M vs Q2 2021N/M vs Q1 2022
Operating Income-$29,188,000N/M
Operating Cash Flowderived-$29,012,000N/M
Free Cash Flowderived-$29,376,000N/M
Margins · derived
Operating margin-650.1%+7687.2 pt vs Q2 2021
Net margin-608.3%+7675.2 pt vs Q2 2021
What the release said
The release
Same quarter
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Revenue | $4.49M | $279.00K | $0.00 |
| Net Income | -$27.31M | -$23.11M | -$15.72M |
| EPS Diluted | -$0.66 | -$0.63 | -$2.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR